US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BETTERLIFE PHARMA INC.

0.0634

+0.00081.28%

Volume:1.52K

Turnover:96.08

Market Cap:10.03M

PE:- -

High:0.0634

Open:0.0634

Low:0.0634

Close:0.0626

52wk High:0.1269

52wk Low:0.0476

Shares:158.18M

Float Shares:109.91M

Volume Ratio:0.08

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

ROE:-4416.54%

ROA:-357.33%

PB:-1.47

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BetterLife provides update on neuroplastogenic activity of BETR-001

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BETRF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BETRF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BETRF\",,,,,undefined,":{"symbol":"BETRF","market":"US","secType":"STK","nameCN":"BETTERLIFE PHARMA INC.","latestPrice":0.0634,"timestamp":1756843200000,"preClose":0.0626,"halted":0,"volume":1515,"delay":15,"floatShares":109905953,"shares":158182581,"eps":0,"marketStatus":"Not Yet Opened","change":0.0008,"latestTime":"09-02 16:00:00 EDT Delay","open":0.0634,"high":0.0634,"low":0.0634,"amount":96.08234999999999,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756886400000},"marketStatusCode":0,"adr":0,"exchange":"OTCQB","adjPreClose":0.0626,"volumeRatio":0.083127},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BETRF\",,,,,undefined,":{"symbol":"BETRF","floatShares":109905953,"roa":"-357.33%","roe":"-4416.54%","lyrEps":0,"volumeRatio":0.083127,"shares":158182581,"dividePrice":0,"high":0.0634,"amplitude":0,"preClose":0.0626,"low":0.0634,"week52Low":0.0476,"pbRate":"-1.47","week52High":0.1269,"institutionHeld":0,"latestPrice":0.0634,"eps":0,"divideRate":0,"volume":1515,"delay":15,"open":0.0634,"prevYearClose":0.072025,"prevWeekClose":0.0626,"prevMonthClose":0.0626,"prevQuarterClose":0.0607,"fiveDayClose":0.0643,"twentyDayClose":0.0717,"sixtyDayClose":0.0649},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BETRF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-27","symbol":"BETRF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1735275600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-06-27","symbol":"BETRF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1719460800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-12-29","symbol":"BETRF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1703826000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-09-27","symbol":"BETRF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1695787200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-05-30","symbol":"BETRF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1685419200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BETRF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BETRF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BETRF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538751744","title":"BetterLife provides update on neuroplastogenic activity of BETR-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2538751744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538751744?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:16","pubTimestamp":1748434568,"startTime":"0","endTime":"0","summary":"BetterLife (BETRF) Pharma recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new par...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/betterlife-provides-update-on-neuroplastogenic-activity-of-betr-001-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/betterlife-provides-update-on-neuroplastogenic-activity-of-betr-001-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BETRF","BK4007","BK4229","BETR"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","MYCOF","GHRS","ALID","MNMD","CMND","SILO","PSYGF","SPRC","CMPS","MIRA","FLHLF","PBM","QNTM","BK4139","PHRRF","AGNPF","ENVB","IXHL","BETRF","SEEL","SNPX","ENTBF","BK4168","BK4202","MDXXF","RLMD","BK4007","CYBN","NRXP","KTTA","BK4539","DRUG","ATAI","NUMIF","OPTHF","RVVTF"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMPS","PSYGF","QNTM","KTTA","BK4547","FLHLF","CYBN","SILO","BK4539","OPTHF","SPRC","RVVTF","NUMIF","PHRRF","MIRA","ATAI","BK4139","PBM","DRUG","ALID","SEEL","RLMD","BK4168","BETRF","MNMD","IXHL","MYCOF","NRXP","MDXXF","BK4007","CMND","ENTBF","SNPX","GHRS","AGNPF","BK4202"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBM","ENVB","PHRRF","SPRC","MNMD","OPTHF","BK4168","BK4539","BK4139","ALID","SNPX","ATAI","MDXXF","SILO","NRXP","RLMD","DRUG","BETRF","IXHL","ENTBF","CYBN","MIRA","PSYGF","RVVTF","QNTM","CMND","CMPS","BK4547","SEEL","AGNPF","BK4007","NUMIF","FLHLF","KTTA","MYCOF","BK4202","GHRS"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BETRF\",params:#limit:6,delay:false,,,undefined,":[]}}